Itulazax 12 SQ-Bet / ALK-Abello - LARVOL DELTA

Nasal allergen challenge with dissolved birch tree pollen tablets. (PubMed, Sci Rep) - "This clinical trial evaluated the feasibility of using dissolved birch pollen tablets, ITULAZAX 12-SQ Bet (ALK-Abelló) tablets as an alternative for NAC...The method demonstrated a sensitivity of 96% and a specificity of 95%. These findings support the use of dissolved ITULAZAX as a reliable and accessible allergen source for nasal allergen challenges in both clinical practice and research."

Journal • Allergy • Immunology • Inflammation

NAC: Nasal Allergen Challenge Test as a Method to Detect Clinical Reactivity Against Birch Pollen (clinicaltrials.gov) - P=N/A | N=89 | Completed | Sponsor: Karolinska Institutet | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Dec 2024 | Trial primary completion date: Dec 2025 ➔ Dec 2024

Trial completion • Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

ACARIZAX approved in Canada for treatment of young children (GlobeNewswire) - "ALK...today announced that Health Canada has approved ALK’s ACARIZAX tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65...The approval is based on the largest-ever paediatric AIT Phase 3 clinical trial, MT-12, involving 1,460 children aged five to 11 in North America and Europe...In parallel, separate regulatory reviews of ALK’s tree pollen allergy tablet ITULAZAX are ongoing in Europe and Canada, for use in young children and adolescents. These reviews are expected to complete in the middle of 2025..."

Canada approval • EMA approval • Allergic Rhinitis • Allergy • Immunology

NAC: Nasal Allergen Challenge Test as a Method to Detect Clinical Reactivity Against Birch Pollen (clinicaltrials.gov) - P=N/A | N=90 | Recruiting | Sponsor: Karolinska Institutet

New trial • Allergic Rhinitis • Immunology • Inflammation